您的位置：首页 > 产品中心 > 134575-17-0， CP-101537
CP-101537
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 3072652 | 5 MG | 1500 | |||
| 3072652 | 25 MG | 5420 |
产品别名
134575-17-0
CP-101537
N-(1a,5a,6a)-3-Azabicyclo[3.1.0]hex-6-yl-carbamic acid 1,1-dimethylethyl ester
PF-3339644
MN-2633
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C10H18N2O2 |
| Molecular weight | 198.26 |
| EC number【EC 号】 | 429-170-8 |
| PubChem Substance ID【PubChem化学物质编号】 | 329823699 |
| Biochem/physiol Actions【生化/生理作用】 | CP-101537 is a MMP inhibitor, candidate drug for myocardial infarction therapy, and antibacterial. |
| Other Notes【其他说明】 | This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. |
| Legal Information【法律信息】 | Sold for research purposes under agreement from Pfizer Inc. Pfizer is a registered trademark of Pfizer, Inc. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| manufacturer/tradename | Pfizer® |
| color【颜色】 | white to off-white |
| solubility【溶解性】 | DMSO: >20 mg/mL |
| originator【创始人】 | Pfizer |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | CC(C)(C)OC(=O)N[C@H]1[C@@H]2CNC[C@H]12 |
| InChI | 1S/C10H18N2O2/c1-10(2,3)14-9(13)12-8-6-4-11-5-7(6)8/h6-8,11H,4-5H2,1-3H3,(H,12,13)/t6-,7+,8+ |
| InChI key | QIYOMZXJQAKHEK-JIGDXULJSA-N |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Pictograms【象形图】 | GHS05,GHS07,GHS08 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H302 - H317 - H318 - H373 |
| Precautionary Statements | P260 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P314 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2 |
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
